Anti-Inflammatory Strategies in Inflammatory Bowel Disease

Inflammatory bowel disease (IBD) encompasses chronic disorders of the gastrointestinal tract, notably Crohn’s disease and ulcerative colitis, characterised by relapsing inflammation, mucosal injury and compromised barrier function. Contemporary anti-inflammatory strategies span a spectrum from conventional small‐molecule drugs and biologics to emerging nutraceutical and microbiome‐based interventions. On the pharmaceutical front, corticosteroids, aminosalicylates and immunomodulators such as thiopurines and methotrexate remain foundational, while monoclonal antibodies targeting tumour necrosis factor-α (TNF-α), interleukin-12/23 and integrins have revolutionised moderate to severe disease management. Small‐molecule inhibitors of Janus kinases (JAKs) offer an oral alternative by interfering with intracellular cytokine signalling. Beyond these, antioxidant and immunomodulatory phytochemicals—polyphenols, flavonoids and lignans—are under investigation for their ability to modulate redox homeostasis, inhibit nuclear factor-κB (NF-κB) and activate nuclear factor erythroid 2-related factor 2 (Nrf2) pathways. Restoration of epithelial integrity via enhancement of tight junction proteins and targeted manipulation of the gut microbiota through prebiotics, probiotics or faecal microbiota transplantation also show promise. Innovative approaches include nanoparticle delivery systems, gene therapy and personalised modulation of immune–microbiome interactions, reflecting the global imperative to develop durable, safe and accessible therapies.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Anti-Inflammatory Strategies in Inflammatory Bowel Disease publication trend

The graph below shows the total number of articles in anti-inflammatory strategies in inflammatory bowel disease across all publications each year (not limited to Nature Index journals).

Technical terms

Cytokines: Small signalling proteins released by immune cells that modulate inflammation and cell communication.

Tumour necrosis factor-α (TNF-α): A pro-inflammatory cytokine central to the pathogenesis of IBD and a key target for biologic therapies.

Nuclear factor-κB (NF-κB): A transcription factor that regulates genes involved in inflammatory and immune responses.

Nuclear factor erythroid 2-related factor 2 (Nrf2): A master regulator of antioxidant defence that induces expression of cytoprotective enzymes.

Janus kinase inhibitors (JAK inhibitors): Small‐molecule drugs that block JAK–STAT signalling downstream of multiple cytokine receptors.

Tight junctions: Protein complexes between epithelial cells that maintain gut barrier integrity and regulate paracellular permeability.

Microbiota: The community of microorganisms residing in the gut, influencing immune homeostasis and mucosal health.

References

1. Caffeic Acid Supplement Alleviates Colonic Inflammation and Oxidative Stress Potentially Through Improved Gut Microbiota Community in Mice. Frontiers in Microbiology (2021).
2. Oxidative stress, hormones, and effects of natural antioxidants on intestinal inflammation in inflammatory bowel disease. Frontiers in Endocrinology (2023).